Effects of menopausal hormone therapy on bone turnover markers in women after surgical menopause
Not Applicable
- Conditions
- Surgical menopause womenBone lossSurgical menopauseBone turnover markersSerum CTXSerum P1NP
- Registration Number
- TCTR20190808004
- Lead Sponsor
- Ratchadapiseksompotch Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- Female
- Target Recruitment
- 48
Inclusion Criteria
Premenopausal women age 40-55 years
Planned surgical menopause due to benign conditions
Exclusion Criteria
Secondary amenorrhea
Receiving hormone therapy
Receiving glucocorticoid more than 3 months
Underlying disease affected bone turnover markers eg DM, Hyperparathyroidism
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of bone turnover markers, between hormone treatment and no treatment 12 weeks Serum CTX
- Secondary Outcome Measures
Name Time Method Correlation between age, FSH level at surgical menopause and change of bone turnovers markers 12 weeks Serum FSH, Serum CTX, Serum P1NP